FDA approves oral semaglutide pill

The U.S. Food and Drug Administration has approved Wegovy tablets, an oral semaglutide product from Novo Nordisk, for chronic weight management, according to FDA approval documents and the drug’s prescribing information. The approval gives obesity patients the first oral GLP-1 option in a market dominated by weekly injections. FDA records show the tablet approval was issued in 2025, and the agency later updated labeling in 2026 to align tablet and injection prescribing information. Novo Nordisk has described the product as the first oral GLP-1 approved in the United States for weight management. ### Which drug was approved, and for whom? FDA labeling says Wegovy tablets are indicated, with diet and physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults who are overweight with at least one weight-related condition. The same label also includes a cardiovascular risk-reduction indication for adults with established cardiovascular disease and obesity or overweight. The approved tablet is semaglutide, the same active ingredient used in Novo Nordisk’s injectable Wegovy and diabetes drug Ozempic, but in an oral formulation. Novo Nordisk says oral semaglutide had already been marketed for type 2 diabetes before the weight-management approval, making the obesity clearance an expansion of the company’s oral GLP-1 franchise. ### What do the FDA documents say about the timing? (accessdata.fda.gov) FDA approval records show the original approval letter for Wegovy tablets was issued in 2025 under application 218316. A separate FDA approval letter dated 2026 says the agency completed review of supplemental applications to align the labeling of Wegovy injection and Wegovy tablets. Novo Nordisk’s corporate materials published in 2026 also refer back to 2025 as the year semaglutide in a pill was approved in the United States for weight management. (novonordisk.com) That means reports dated May 16, 2026 are describing an already-approved product rather than a same-day FDA decision. ### How much weight loss did Novo Nordisk report? Novo Nordisk’s OASIS 1 trial materials say once-daily oral semaglutide 50 mg was studied in adults with overweight or obesity without type 2 diabetes. (accessdata.fda.gov) In that trial, the company reported mean weight loss results that supported its obesity filing program for oral semaglutide. (novonordisk.com) Novo Nordisk’s 2025 annual report says oral semaglutide 25 mg became the first once-daily oral GLP-1 approved for chronic weight management and delivered 16.6% weight loss if all study participants adhered to treatment. The company said that result was on par with injectable Wegovy 2.4 mg. ### What warnings and restrictions come with the pill? FDA labeling for Wegovy tablets carries a boxed warning about thyroid C-cell tumors observed in rodents and says it is unknown whether the drug causes such tumors in humans. (sciencehub.novonordisk.com) The label says the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. (annualreport.novonordisk.com) The prescribing information also lists gastrointestinal adverse reactions and other precautions already familiar from injectable semaglutide products. FDA’s 2025 approval letter for the tablet includes postmarketing requirements, including pediatric pharmacokinetic and exposure-response analyses for patients with obesity ages 6 to under 12 years. ### What still has to happen before patients see the impact? (accessdata.fda.gov) Novo Nordisk has not, in the FDA documents reviewed here, set out U.S. commercial pricing or broad insurance coverage terms for Wegovy tablets. The company’s U.S. news pages show it has been actively adjusting access programs for obesity drugs in 2026, including a Medicare bridge program tied to Wegovy products. FDA materials now provide the core facts patients and prescribers will use first — indication, contraindications, dosing framework and safety language. (accessdata.fda.gov) The next concrete milestones are payer coverage decisions, launch terms from Novo Nordisk and any additional FDA label updates tied to postmarketing work already listed in the approval record. (accessdata.fda.gov) (novonordisk-us.com)